Vanda Pharmaceuticals Inc.
VNDA Healthcare Biotechnology
Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.
Follow VNDA
Vanda Pharmaceuticals Inc. (VNDA) EV/Sales
As of 16 October 2026, Vanda Pharmaceuticals Inc. (VNDA) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −1.4× (November 2023) to 7.6× (December 2018); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | — |
| FY2024 | −0.5× | — |
| FY2023 | −0.6× | — |
| FY2022 | −0.2× | — |
| FY2021 | 1.7× | 15.48% |
| FY2020 | 1.4× | (42.58%) |
| FY2019 | 2.5× | (54.65%) |
| FY2018 | 5.6× | 65.38% |
| FY2017 | 3.4× | (8.58%) |
| FY2016 | 3.7× | 61.44% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.9× | (4.08%) |
| Mar 2026 | 1.0× | (18.96%) |
| Dec 2025 | 1.2× | 6,403.24% |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CABA Cabaletta Bio, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. | 0.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.6× |
| PRLD Prelude Therapeutics Incorporated compare | 7.5× |
| XFOR X4 Pharmaceuticals, Inc. compare | 12.4× |
| LCTX Lineage Cell Therapeutics, Inc. compare | 14.8× |
| ACIU AC Immune compare | 31.3× |
| IKT Inhibikase Therapeutics, Inc. compare | 495× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)